Contract Manufacturing and Development

Historically, Inyx has successfully developed, industrialised and commercially manufactured a wide range of hormonal, cardiovascular, pulmonary and allergy solid dose and capsule products for large generic, biotech and major Pharmaceutical brand companies at its various locations within the United Kingdom and USA. Our clients include Astra Zeneca, Sanofi-Aventis, King Pharmaceuticals, UCB Pharma Ltd, Kos Pharmaceuticals and Merck Generics, to name a few.

Inyx has expertise and technologies that we offer to our clients and we have one of the most comprehensive platforms of solid dose (including granulation and film coating process for solvent and aqueous formulations, as well as sugar coating capability); inhalation drug delivery technologies, including Metered Dose Inhalers (MDIs), which is the dominant delivery modality for asthma treatment; Dry Powder Inhalers (DPIs) that continues to gain an increasing share of asthma treatment and expected to become more appropriate than MDIs for non-respiratory inhalation therapy treatments; and Metered Dose Nasal Sprays and Oral Sprays for allergies, hay fever, rhinitis, bronchitis and colds treatments

Inyx has always had a long term strategy to grow vertically and horizontally and therefore firmly believes it will add increased capabilities and resources that can also be brought to bear and subsequently benefit our customers considerably and through both organic growth and by acquisitions we intend to be a major service provider in the pharmaceutical arena for many years. More importantly by focussing on quality, versatility, innovative solutions and customer service, providing comprehensive contract manufacturing and packaging solutions, developing and investing in specialized manufacturing processes, which have significant barriers to entry and enhancing our clients' competitive position by accelerating time to market for new and innovative pharmaceutical products we believe we can offer an enhanced service to our clients. To further these strategic aims we continue to invest in our current development and manufacturing capabilities at both our European and USA facilities to ensure they meet all the necessary regulatory requirements and are both flexible and robust to meet a wide range of product requirements.

This experience and underpinning knowledge provides further testimony to the benefits we share with our clients by working closely together and building upon this to ensure future success and business growth. The recent success and responsiveness of Inyx to support a wide range of major client's development and scale up programs further demonstrates that Inyx is committed to working with our partners for the long term.

Additionally Inyx has the capability to scale up and industrialize various products has a fully equipped pilot scale facilities to facilitate such activities. In addition Inyx is the first of few companies with proven expertise in the conversion to non-ozone-depleting aerosol pharmaceuticals, and the only company with expertise in both CFC (chlorofluorocarbon) to HFA (hydrofluoroalkane) conversion and CFC to isobutane conversion.

Inyx also has a patented platform technology that utilizes a novel lipid-binding matrix for delivering incompatible or unstable drug substances which enhances delivery of not only single molecule but also combination inhalation-therapy drugs and as you know combined drug treatments is one of the fastest-growing areas today and it is something Inyx is well equipped to provide a service for.

We already have the solid dose, pump spray and metered dose inhaler capability and necessary infrastructure globally established and therefore have synergistic group capacity/capability to offer significant logistical benefits to our clients with regards to the overall manufacturing price and attainment of regulatory requirements in an expeditious manner and with less risk to potential new product introduction timelines.

Development Focus
We continue to focus our development activities in providing a service for generic products and innovative drug delivery systems for our clients, including potential line extensions of established products or overcoming formulation and present propellant incompatibility and consumer-use issues in solid dose and aerosol pharmaceuticals, plus combination inhalation-therapy drugs. Inyx also has considerable Solid Dose, Metered dose inhalers, nasal pumps, topical aerosols and oral sprays – for respiratory, allergy, dermatological, topical and cardiovascular treatments development expertise and knowledge and has previously developed a wide range of products for a number of major pharmaceuticals that has led to a successful approval.

Manufacturing Capabilities
We have a wide range of manufacturing services we offer to our clients: